Charles Sawyers and colleagues have conducted a small early-stage clinical study to assess target modulation by the small-molecule inhibitor rapamycin. Rapamycin is approved to treat renal cancer ...

The company’s therapeutic strategy consists of designing tumor-directed nucleotide prodrugs. Once taken up by the tumor cells, the nucleotide prodrugs are cleaved, and the nucleotides can ...

But out of all the supplements and drugs he takes for 'living healthy forever', one key medicine that Bryan and other ...

Encapsulated rapamycin is expected to prevent disease progression by inhibiting mTOR, a protein kinase that has been shown to be overexpressed in FAP polyps. The Food and Drug Administration (FDA ...

The current interest in prodrugs is evident. Since 2008, the FDA has approved over 30 prodrugs, and approximately 10% of all marketed drugs worldwide can be considered prodrugs. Consequently, the ...